Recent news highlights Celcuity's wider FY25 loss, progress toward potential gedatolisib launch, FDA acceptance of NDA, and notable investor activity in the stock.

• Celcuity reported a wider net loss for fiscal year 2025 and highlighted progress toward potential launch of gedatolisib [N1].
• The company announced financial results for Q4 and FY25 on March 25, 2026 [N2].
• A significant investor placed a $170 million bet on Celcuity amid FDA review for its breast cancer drug, reflecting strong market interest [N3].
• Apis Capital trimmed holdings of Celcuity stock according to a recent SEC filing [N4].
• An investment manager increased holdings by adding 135,000 shares as per latest SEC filing [N5].
• Celcuity stock soared approximately 700% in a year, supported by a $17 million purchase by a key investor creating a top two position [N8].

Gedatolisib's comprehensive inhibition of the PAM pathway and differentiated tolerability profile could address unmet needs in HR+/HER2- advanced breast cancer, particularly in patients progressing after CDK4/6 therapy. The completion of enrollment and reported results from the Phase 3 VIKTORIA-1 trial cohort 1, along with ongoing trials including VIKTORIA-2 and prostate cancer studies, demonstrate clinical progress. FDA acceptance of the NDA with Priority Review and regulatory designations support potential for expedited approval. Strong liquidity and ongoing investor interest provide financial resources to support late-stage development and potential commercialization efforts.

Celcuity has not yet commercialized any products and has incurred significant operating losses. The company carries substantial indebtedness, which could limit financial flexibility and increase risk of default or restrictive covenants. Clinical development and regulatory approval of gedatolisib remain uncertain, with risks of delays, supply chain interruptions, or failure to demonstrate sufficient efficacy and safety. Competition from other therapies targeting the PAM pathway or breast cancer could limit market opportunity. Failure to secure additional financing or successfully commercialize gedatolisib would materially and adversely impact the business.

Celcuity's moat is based on its lead drug candidate gedatolisib, which offers comprehensive inhibition of the PAM pathway by targeting all class I PI3K isoforms and both mTOR complexes. This broad mechanism addresses adaptive resistance mechanisms that limit the efficacy of single-component inhibitors. Gedatolisib's intravenous administration and differentiated pharmacokinetics contribute to better tolerability compared to oral PI3K or mTOR inhibitors, which have challenging toxicity profiles. The drug has received FDA Fast Track and Breakthrough Therapy designations, supporting expedited development and regulatory review. The company's extensive clinical trial program and intellectual property rights under a license agreement with Pfizer further support its competitive position. However, the biotech industry is highly competitive with rapid technological evolution and significant financial and regulatory challenges.

• Clinical and Regulatory Risk: The success of Celcuity depends on the clinical development, regulatory approval, and commercialization of gedatolisib. Delays or failures in clinical trials, adverse safety findings, or regulatory setbacks could materially impact the company.
• Financial and Indebtedness Risk: The company has significant indebtedness which may limit cash flow, flexibility, and ability to meet debt obligations. Failure to comply with covenants or repay debt could lead to default and adversely affect operations.
• Competition Risk: Celcuity faces competition from larger pharmaceutical and biotech companies with greater resources. Competing therapies may limit market acceptance and commercial success of gedatolisib.
• Manufacturing and Supply Chain Risk: Celcuity relies on third-party contract manufacturing organizations for drug substance and product supply. Disruptions or non-compliance with regulatory standards could affect clinical and commercial supply.
• Market and Commercialization Risk: The company has not yet commercialized any products and must build commercial infrastructure. Market acceptance, pricing, reimbursement, and sales execution pose risks to future revenue generation.

• Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications [S1].
• The lead therapeutic candidate is gedatolisib, a kinase inhibitor targeting all class I PI3K isoforms and mTOR complexes (mTORC1 and mTORC2), inducing comprehensive inhibition of the PI3K/AKT/mTOR (PAM) pathway [S1].
• Gedatolisib's mechanism and pharmacokinetics differentiate it from other therapies targeting PI3Kα, AKT, or mTORC1 alone or together [S1].
• The company has completed enrollment and reported detailed results for cohort 1 (PIK3CA wild-type tumors) in the Phase 3 VIKTORIA-1 trial evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- advanced breast cancer (ABC) patients [S1].
• Enrollment for cohort 2 (PIK3CA mutant-type tumors) in VIKTORIA-1 is complete, with topline data expected in Q2 2026 [S1].
• The Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as first-line treatment for endocrine treatment resistant HR+/HER2- ABC is ongoing, with safety run-in completed in Q1 2026 [S1].
• A Phase 1b/2 trial (CELC-G-201) is ongoing, evaluating gedatolisib with darolutamide in metastatic castration resistant prostate cancer (mCRPC), with preliminary Phase 1 data reported in Q4 2025 [S1].
• Gedatolisib was granted FDA Fast Track designation in January 2022 and Breakthrough Therapy designation in July 2022 for HR+/HER2- ABC after progression on CDK4/6 therapy [S1].
• The FDA accepted the New Drug Application (NDA) for gedatolisib on January 16, 2026, granting Priority Review with a PDUFA goal date of July 17, 2026 [S1].
• Gedatolisib is administered intravenously on a four-week cycle, once a week for three weeks followed by one week off, which is better tolerated than oral PI3K or mTOR inhibitors that have significant side effects [S1].
• Clinical data show gedatolisib is more potent and efficacious than single component PAM inhibitors and induces significant cytotoxic effects in breast cancer cell lines regardless of PIK3CA mutation status [S1].
• As of December 31, 2025, 1,127 patients and healthy volunteers have received gedatolisib in 12 clinical trials, including 123 patients treated with gedatolisib as a single agent and 968 patients treated in combination with other anti-cancer agents [S1].
• The company has agreements with contract manufacturing organizations (CMOs) for formulation, manufacturing, and distribution of gedatolisib for clinical and potential commercial supply [S1].
• Celcuity had 155 full-time employees as of December 31, 2025, mostly in research and development, with hiring begun for commercial launch preparation [S1].
• The company has not yet commercialized any pharmaceutical product and has incurred significant operating losses since inception, financing operations through equity, convertible notes, and loans [S1].
• As of December 31, 2025, Celcuity had $165.7 million in cash and equivalents, $275.8 million in short-term investments, total current assets of $465.7 million, and current liabilities of $44.2 million, resulting in a current ratio of 10.55 and a cash ratio of 10 [S1].
• The company reported a net loss of $177.0 million and basic and diluted EPS of -$3.79 for the fiscal year ended December 31, 2025 [S1].
• Celcuity had $338.8 million aggregate principal indebtedness as of December 31, 2025, including $130.0 million secured term loans and $201.3 million senior notes due 2031, with an additional $220.0 million in incremental term loans available upon achievement of clinical milestones and product revenue thresholds [S1].
• The company faces risks related to indebtedness that could limit cash flow, flexibility, and ability to meet debt obligations, including potential defaults and restrictive covenants [S1].
• Celcuity's business depends on successful clinical development, regulatory approval, and commercialization of gedatolisib, with risks of delays, supply chain interruptions, and failure to generate revenue [S1].
• Recent news highlights include wider FY25 loss reported, progress toward potential gedatolisib launch, FDA acceptance of NDA, and significant investor activity in the stock [N1][N2][N3][N4][N5][N8].